TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00419913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: DHEA 25 mg tid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dehydroepiandrosterone
Description: DHEA 25 mg tid
Study: NCT01757756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pf-05175157
Description: 200-mg administered twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo administered twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam 3-mg admistered as single doses on Day 0 and Day 11.
Study: NCT02156232

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS
Description: TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS
Description: TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPSS embolization
Description: Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
Study: NCT02546427

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Helical TomoTherapy (HT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Permanent Prostate Implant (PPI)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Study: NCT00483158

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finafloxacin hydrochloride
Description: Tablets, oral single dose and multiple dose once daily for 7d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finafloxacin hydrochloride
Description: Tablets, oral single dose and multiple dose once daily for 7d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin hydrochloride
Description: Tablets, oral single dose and multiple dose once daily for 7d
Study: NCT04706169

Intervention type: DEVICE
Intervention: Surface Electromyography
Description: SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.

Intervention type: DEVICE
Intervention: Surface Electromyography
Description: SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
Study: NCT02827994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurophysiology of pain education and exercises
Description: Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session.
Study: NCT03130023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter with ORI
Description: Pulse oximeter that measure Oxygen Reserve Index
Study: NCT03162497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 15mg/g eyedrops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg per os
Study: NCT00356863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing awareness to cardiac rehabilitation programs
Description: Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
Study: NCT00583817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular stent-graft implantation
Description: Endovascular repair of aorta

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular stent-graft implantation
Description: Endovascular repair of aorta

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular stent-graft implantation
Description: Endovascular repair of aorta
Study: NCT03791905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: chemotherapy drug
Study: NCT00873912

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
Study: NCT01731717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active monitoring
Description: General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Description: Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-help
Description: Patient works with online self-help program Deprexis under general physician's supervision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient psychotherapy
Description: Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment
Description: Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined psychotherapy and psychopharmacological treatment
Description: Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group: treatment as usual
Description: treatment as usual
Study: NCT04010019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Facebook Condition
Description: The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Facebook Condition
Description: The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
Study: NCT01915719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early non invasive ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy only
Study: NCT02943967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CXL + PRK group
Description: Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK group
Description: Photorefractive keratotomy alone was performed in contra lateral eyes
Study: NCT04171024

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electrical stimulation
Description: A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous diaphragm electrical stimulation
Description: A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
Study: NCT01591889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: 500 mg tablet
Study: NCT05166681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical wound suturing
Description: single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical wound suturing
Description: single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
Study: NCT01161459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii
Description: Tripterygium wilfordii 120mg/d Prednisone 30mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FK506
Description: capsule
Study: NCT03100500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149
Description: QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
Study: NCT03791905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: chemotherapy drug

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: radiotherapy technique

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: radiotherapy technique
Study: NCT02352974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT03547583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets
Description: Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets
Description: Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
Study: NCT00389831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine Nasal Spray
Description: Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Daily single dose of placebo delivered as single puff of nasal spray solution
Study: NCT01040884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiSight Needle Guidance System
Description: ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
Study: NCT02011750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate treatment
Description: Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
Study: NCT03642522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
Study: NCT00003621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01782482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Hydrogel contact lens with color
Study: NCT03867955

Intervention type: OTHER
Intervention: Collection of datas
Description: Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
Study: NCT04107155

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight Management Formulation
Description: Saffron extract and Gynostemma extract with hesperidin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03547583

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and sham up-titration at weeks 2, 4, and 6
Study: NCT03501290

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fortimel® Protein supplementation
Description: Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month.
Study: NCT02998567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: In arm 1 (escalation) and 2 (expansion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: In arm 1 (escalation) and 2 (expansion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In arm 1 (escalation) and 2 (expansion).
Study: NCT03791905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Using PET to evaluate response to induction chemotherapy
Study: NCT04107155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout with Suggestions for Healthy Eating and Overall Health
Description: Suggestions for Healthy Eating and Overall Health

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Handout with Suggestions for Healthy Eating and Overall Health
Description: Suggestions for Healthy Eating and Overall Health
Study: NCT01478737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal dexamethasone implant
Description: Intravitreal Ozurdex after vitrectomy
Study: NCT01444105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent
Description: Implantation of two iStent devices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLT
Description: Laser treatment
Study: NCT03728933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 1 milligram/24 hours
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 1 milligram/24 hours
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 2 milligram/24 hours
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine 2 milligram/24 hours
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
Study: NCT00582907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: 2.2 mg/kg/wk by subcutaneous injection, for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo by subcutaneous injection weekly for 3 months
Study: NCT01204788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic White Cell Transfusion
Description: Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic White Cell Transfusion
Description: Radiated white blood cell transfusions daily only with infection (or persistent fever)
Study: NCT00639457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Oral 30mg/day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Oral 30mg/day for 16 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
Study: NCT02998567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In arm 1 (escalation) and 2 (expansion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In arm 1 (escalation) and 2 (expansion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: In arm B2 (lung expansion) replacing guadecitabine
Study: NCT01785069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection
Description: Surgical implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection
Description: Surgical implant
Study: NCT03144960

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical Thrombectomy
Description: mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
Study: NCT01364233

Intervention type: DEVICE
Group type: OTHER
Intervention: MotifMESH
Description: Polytetrafluoroethylene (cPTFE) macroporous mesh